Featured Research

from universities, journals, and other organizations

Nanoparticle Delivery System Developed To Induce Immunity To Certain STDs

Date:
May 4, 2009
Source:
University of California - Los Angeles
Summary:
Chlamydia trachomatis is the most common bacterial agent of sexually transmitted infections and occurs in 1 million cases a year and is the largest reportable infection in the US. Researchers have designed a unique method for inducing immunity to the infection. The findings could accelerate progress toward developing a vaccine to guard against the infections of Chlamydia trachomatis which frequently lead to reproductive dysfunction and profound local inflammation that requires medical attention.

Chlamydia trachomatis is the most common bacterial agent of sexually transmitted disease, accounting for more than a million reported infections in the United States each year.

Related Articles


Researchers at the California NanoSystems Institute (CNSI) at UCLA and the David Geffen School of Medicine at UCLA have now designed a unique method for inducing immunity to the infection. The findings could accelerate progress toward the development of a vaccine against Chlamydia trachomatis infections, which can lead to reproductive dysfunction and profound local inflammation requiring medical attention.

Their study describes the first use of a novel vaccine platform that utilizes an engineered nanoparticle delivery system.

The research team, a partnership between UCLA immunologists and nanotechnologists, is led by Kathleen Kelly, an associate professor of pathology and laboratory medicine and a CNSI member, and Leonard H. Rome, interim director of the CNSI and a professor of biological chemistry. The team also includes Cheryl I. Champion, Valerie A. Kickhoefer, Guangchao Liu, Raymond J. Moniz, Amanda S. Freed, Lisa L. Bergmann, Dana Vaccari, Sujna Raval-Fernandes and Ann M. Chan.

The researchers were able to uncover a surprising connection between vault nanoparticles and mucosal immunity. Vaults are barrel-shaped nanoscale capsules found in the cytoplasm of all mammalian cells that can be engineered to serve as potential therapeutic delivery devices.

"The primary goal of vaccines is to generate robust cell-mediated immune responses at mucosal surfaces while reducing overall inflammation caused by infection," Kelly said. "We found that vault nanoparticles containing immunogenic proteins can act as 'smart adjuvants' for inducing protective immunity at mucosal surfaces while avoiding destructive inflammation."

Adjuvants are molecular triggers that initiate vaccine responses.

Mucosal immune responses provide superior protection against disease, but there are currently no adjuvants approved by the Food and Drug Administration that are capable of stimulating cell-mediated immune responses within mucosal tissues. Mucosal surfaces are hostile environments, and immunogenic proteins require added protection for delivery to cells in order to induce immunity.

The team produced recombinant vaults through a process that involved the molecular engineering of these naturally occurring cellular structures to test the concept that vaults can have a broad nanosystems application as malleable nanocapsules.

"Our research team wanted to find out if recombinant vaults could provide such protection by encapsulating an antigen and preserving its functional characteristics, even within the cells," Kelly said.

The internal cavity of the recombinant vault nanoparticle is large enough to hold multiple immunogenic proteins, and because vaults are the size of small microbes, a vault particle containing such proteins can be easily absorbed by the targeted cells.

Vaults are being studied for use in the delivery of a range of potential therapeutics, including synthetic and natural compounds, nucleic acids, and proteins. Recombinant vaults containing proteins are easily produced, making vaults a viable vaccine delivery platform.

"Adjuvants provide the necessary assistance to vaccine preparations for promoting immunity or protection from infection by combining the vault with a part of the Chlamydia organism," Kelly said. "We were able to design a vaccine that prevented Chlamydia infection better than other designs."

The research team found that when they immunized female mice with recombinant vaults containing a component of Chlamydia and then exposed the mice to a vaginal challenge with live Chlamydia, their reproductive tracts were protected from severe bacterial infection.

The results suggest that vaults are superior adjuvants for immunization against infections largely limited to mucosal tissues.

"We are encouraged that our findings could accelerate progress toward developing a vaccine to guard against this infection," Kelly said.

The research was supported by the UCLA AIDS Institute and the National Institutes of Health.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.


Journal Reference:

  1. Champion et al. A Vault Nanoparticle Vaccine Induces Protective Mucosal Immunity. PLoS ONE, 2009; 4 (4): e5409 DOI: 10.1371/journal.pone.0005409

Cite This Page:

University of California - Los Angeles. "Nanoparticle Delivery System Developed To Induce Immunity To Certain STDs." ScienceDaily. ScienceDaily, 4 May 2009. <www.sciencedaily.com/releases/2009/04/090430091059.htm>.
University of California - Los Angeles. (2009, May 4). Nanoparticle Delivery System Developed To Induce Immunity To Certain STDs. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2009/04/090430091059.htm
University of California - Los Angeles. "Nanoparticle Delivery System Developed To Induce Immunity To Certain STDs." ScienceDaily. www.sciencedaily.com/releases/2009/04/090430091059.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins